Mechanism
Adipose tissue remodelling
Weight loss with incretin therapy is not just generic fat loss. Imaging studies (DXA, MRI) show preferential reduction of visceral adipose tissue and liver fat, and changes in adipose inflammation markers. These tissue-level changes likely contribute to the cardiometabolic effects observed in trials.
Plain-English explanation
Weight loss with incretin therapy is not just generic fat loss. Imaging studies (DXA, MRI) show preferential reduction of visceral adipose tissue and liver fat, and changes in adipose inflammation markers. These tissue-level changes likely contribute to the cardiometabolic effects observed in trials.
Research-level explanation
DXA and MRI substudies of pivotal phase 3 trials describe consistent visceral and hepatic fat reduction. Mechanistic interpretation continues to evolve.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Weight loss is just calorie restriction. | The pattern of fat loss (visceral > subcutaneous, hepatic fat reduction) differs from typical calorie-restriction-only patterns and is a major reason trial outcomes extend beyond body weight alone. |
Safety relevance
Lean-mass and nutritional safety should be monitored alongside fat-mass reduction, particularly in older adults and those with sarcopenic obesity.
- Imaging changes do not establish definite long-term clinical outcomes.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site